Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT02009488
First received: December 9, 2013
Last updated: August 24, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)